What Do Peptides Do? How Peptides Work in the Body

Key Takeaways

• Primary mechanism: Most biologically active peptides bind specific cell-surface receptors and trigger intracellular signaling cascades that alter cellular behavior.
• Specificity is structural: The amino acid sequence determines which receptor a peptide binds, which explains why small sequence changes produce dramatically different biological effects.
• Endogenous role: The body relies on peptides continuously — for blood glucose regulation, appetite signaling, fluid balance, immune defense, and neurological function.
• FDA-approved context: Drugs like semaglutide and tirzepatide, FDA-approved for type 2 diabetes and chronic weight management, work by mimicking and extending endogenous peptide mechanisms the body already uses.
• Research-grade compounds: Many investigational peptides labeled "for research use only" have proposed mechanisms from preclinical models; they are not approved for human use and human evidence ranges from limited to absent for most compounds in this category.

What Peptides Are

A peptide is a chain of two or more amino acids connected by covalent peptide bonds — the same type of bond that builds proteins, but in a shorter sequence. The StatPearls chapter by Forbes, Kaprive, and Krishnamurthy, published through NCBI Bookshelf, defines peptides as 2 to 50 amino acid chains joined by covalent bonds formed in condensation reactions, distinguishing them from proteins primarily by length and the absence of the complex three-dimensional folding structures proteins adopt. What distinguishes a peptide biologically is not just its length but its functional role: most peptides act as signals rather than structures. That signaling function — binding a receptor, triggering a cascade, altering cell behavior — is the answer to "what do peptides do?"

Peptide bonds and amino acid structure

Each amino acid in a peptide chain has a free amino group at one end and a free carboxyl group at the other, with a variable side chain that defines its chemical character. A peptide bond forms between the carboxyl group of one amino acid and the amino group of the next, releasing a water molecule in a condensation reaction. This directional assembly produces a chain with a fixed N-terminus (amino end) and C-terminus (carboxyl end). The specific sequence of amino acids — the order from N to C — determines how the peptide folds in space and which receptor it binds. Small changes in sequence can produce large changes in function. Sanvictores and Farci, writing in the StatPearls chapter updated in 2023, illustrated how the linear amino-acid sequence underpins all of a molecule's downstream biological properties, using the sickle-cell mutation — a single amino acid substitution — as the paradigm case.

Peptides vs. proteins: where the line is

The conventional boundary places peptides at 2 to 50 amino acids and proteins beyond that, with proteins adopting folded three-dimensional structures that enable enzymatic or structural roles. That boundary is a convention, not a biological absolute. Sanvictores and Farci describe proteins as folded polypeptides — the same linear amino-acid chain, simply longer and folded into secondary and tertiary structure. The functional distinction is more relevant: peptides tend to act as messengers and modulators rather than scaffolds or catalysts. GLP-1 at 30 amino acids is unambiguously a peptide-class hormone; albumin at 585 amino acids is unambiguously a protein. Insulin at 51 amino acids sits at the boundary and is conventionally classified as a protein hormone despite fitting peptide-range length. What matters for clinical purposes is not which side of the definitional line a compound falls on, but what mechanism it uses.

How Peptides Work in the Body

Most biologically active peptides work by binding to specific receptors on cell surfaces, triggering intracellular signaling cascades that alter cellular behavior. The precision of this process is a defining feature of the class: a given peptide binds its target receptor with high specificity, while leaving most other receptor types unengaged. That specificity is what makes peptides therapeutically valuable and physiologically fundamental.

Cell signaling and receptor binding

The primary mechanism for most peptide hormones involves binding to G protein-coupled receptors (GPCRs) — a large superfamily of cell-surface receptors involved in much of the known cellular signaling. When a peptide ligand binds its GPCR, it induces a conformational change in the receptor protein that activates an intracellular G protein, triggering downstream cascades involving second messengers (cAMP, IP₃, DAG) that ultimately alter gene expression, enzyme activity, or ion channel function. Posner and Laporte, in their 2010 review in Progress in Brain Research, reviewed peptide hormone receptor signaling through kinase cascades and transcription-factor activation that drive metabolic and proliferative responses. Langelaan and colleagues, writing in Biochemistry and Cell Biology in 2010, described a membrane-catalysis activation model in which peptide ligands first interact with the lipid bilayer, adopting amphipathic helical conformations that position the peptide for receptor engagement — a two-step activation mechanism relevant to many GPCR-class peptide hormones.

GLP-1 is one of the most thoroughly studied modern examples of this mechanism. Holst's 2007 review in Physiological Reviews reviewed GLP-1 receptor signaling in beta cells, documenting how GLP-1 produced in intestinal L-cells triggers insulin secretion and glucagon suppression in a glucose-dependent manner, while also slowing gastric emptying and reducing appetite through separate receptor populations in the gut and brain. Kim and colleagues, publishing a 2025 structural review in Experimental and Molecular Medicine, reviewed GLP-1R structural biology and drug design, illustrating how atomic-level understanding of receptor binding has enabled the development of semaglutide and tirzepatide as extended-action synthetic analogues. Moiz and colleagues, writing in the American Journal of Medicine in 2025, reviewed GLP-1 signaling in brain and periphery, showing how it influences both brain appetite centers and peripheral metabolism simultaneously — a multi-tissue effect that is characteristic of the class.

Endogenous peptides: what your body already makes

The body synthesizes peptides continuously, relying on them for core physiological regulation:

• Insulin: A 51-amino-acid two-chain peptide hormone that regulates blood glucose by facilitating cellular glucose uptake and suppressing hepatic glucose production. Forbes's 2023 review in Vitamins and Hormones documented insulin's receptor-binding mechanism at atomic resolution.
• GLP-1: A 30-amino-acid incretin peptide produced in the gut after eating. Acts on the pancreas to enhance insulin secretion, on the hypothalamus to reduce appetite, and on the stomach to slow gastric emptying.
• Ghrelin: A 28-amino-acid peptide produced in the stomach that stimulates growth hormone secretion from the pituitary and drives appetite through hypothalamic NPY signaling. Shintani and colleagues, publishing in Diabetes in 2001, showed ghrelin drives feeding via NPY, stimulating food intake via hypothalamic NPY signaling and opposing leptin. Broglio and colleagues, writing in the Israel Medical Association Journal in 2002, reviewed ghrelin's central and peripheral actions — including GH release, appetite, GI function, and cardiovascular effects — illustrating that one peptide can perform multiple physiological roles through different receptor populations.
• Oxytocin: A 9-amino-acid neuropeptide that regulates social bonding, maternal behavior, and parturition. Macdonald and Macdonald, in a 2010 systematic review in the Harvard Review of Psychiatry, reviewed oxytocin's effects on social behavior, memory, and decision-making in controlled human studies.
• Vasopressin (ADH): A 9-amino-acid peptide that controls water reabsorption in the kidney and influences blood pressure.
• Glucagon: A 29-amino-acid pancreatic peptide that mobilizes glucose from glycogen stores during fasting, opposing insulin's actions.

How the body breaks peptides down

Peptides are metabolized by peptidases and proteases — enzymes that cleave peptide bonds at specific sequence sites. This metabolic process is rapid and efficient, which is why most endogenous peptide hormones have short half-lives measured in minutes. Leung and colleagues, in their 2011 review in the Annual Review of Biochemistry, described how ribosomes catalyze peptide bond formation during biosynthesis — the same bond that peptidases later cleave during catabolism. This rapid degradation explains why most therapeutic peptides cannot survive oral ingestion intact, requiring injection or specialized delivery systems. Fetse and colleagues, in a 2023 review in Trends in Pharmacological Sciences, reviewed peptide half-life extension strategies — cyclization, D-amino acid substitution, PEGylation — for pharmaceutical use.

Major Categories of Peptides by Function

Peptides are usefully classified by what they do rather than what they are. The functional categories below each have distinct mechanisms, evidence standards, and clinical contexts.

Hormonal and metabolic peptides

Peptide hormones regulate metabolism, energy balance, and endocrine function. GLP-1 receptor agonists are a widely prescribed current example. Liu and colleagues, writing in Frontiers in Endocrinology in 2024, reviewed dual incretin GLP-1 / GIP agonists, explaining how tirzepatide's simultaneous activation of two receptor types produces additive metabolic effects beyond single-receptor agents. Heise and colleagues, in a Phase 1 RCT published in Lancet Diabetes and Endocrinology in 2022 (N=117), showed tirzepatide improved beta-cell function and insulin sensitivity compared to semaglutide and placebo, quantifying the mechanism-level differences between two peptide drugs in the same class.

Antimicrobial peptides

Antimicrobial peptides (AMPs) are produced by virtually all living organisms as part of innate immunity. They work primarily by disrupting the membrane integrity of pathogens through electrostatic and hydrophobic interactions that are selective for microbial membranes over mammalian cell membranes. Seo and colleagues, in a 2012 review in Molecules, described how short AMPs disrupt pathogen membranes through structure-activity relationships that depend on charge, amphipathicity, and chain length. Huan and colleagues, in a 2020 review in Frontiers in Microbiology, reviewed broad-spectrum AMP mechanisms across bacteria, fungi, parasites, and viruses, including SARS-CoV-2, illustrating the breadth of antimicrobial mechanisms available in this class.

Neuropeptides

Neuropeptides are peptides that act in the nervous system as neurotransmitters, neuromodulators, or neurohormones. Bhat and colleagues, in a 2021 review in Frontiers in Molecular Neuroscience, reviewed neuropeptide behavioral circuits governing feeding, sleep, addiction, learning, and locomotion. Rigney and colleagues, writing in Endocrinology in 2022, reviewed oxytocin and vasopressin social signaling via distinct hypothalamic circuits, documenting how each modulates maternal bonding and social communication — a case study in how two 9-amino-acid peptides with near-identical sequences (differing at positions 3 and 8) produce profoundly different behavioral effects through different receptor selectivity.

Growth hormone-related peptides

Growth hormone-releasing peptides (GHRPs) and growth hormone-releasing hormone (GHRH) analogues are proposed to stimulate growth hormone secretion from the pituitary; tesamorelin is the FDA-approved example, while other compounds in the class remain investigational in humans. Bednarek and colleagues, publishing in the Journal of Medicinal Chemistry in 2000, identified the minimal 4 to 5 amino-acid core of ghrelin needed for receptor activation — an example of how mechanistic understanding enables the design of shorter, more drug-like peptide agonists. Tesamorelin, an FDA-approved GHRH analogue, uses this same class of mechanism and is available by prescription for HIV-associated lipodystrophy.

Tissue-repair and cell-penetrating peptides

Some peptides have been studied for effects on wound healing, tissue repair, and intracellular drug delivery. Thymosin beta-4 is a well-characterized example in the regenerative category: Malinda and colleagues, in a 1999 study in the Journal of Investigative Dermatology, reported accelerated wound re-epithelialization in rat wound models, with reported improvements in the range of 42–61% over control, and Goldstein and Kleinman reviewed the full mechanistic picture — actin binding, cell migration, stem cell signaling, and inflammation modulation — in a 2012 review in Expert Opinion in Biological Therapy reviewing thymosin beta-4 tissue repair applications across dermal, cardiac, and neural contexts. Thymosin beta-4 is not FDA-approved for any human indication; its actin-binding fragment, commonly sold online as TB-500, has been placed on the FDA Category 2 bulk drug substances list, meaning it is not eligible for compounding under Section 503A pending the FDA's safety determination. Cell-penetrating peptides, typically fewer than 30 amino acids, cross cell membranes through endocytosis or direct translocation and are studied as drug delivery vehicles; Derakhshankhah and Jafari, writing in Biomedicine and Pharmacotherapy in 2018, reviewed cell-penetrating peptide delivery mechanisms for delivering therapeutic cargo into cells.

FDA-Approved Peptide Drugs: Mechanisms in Clinical Practice

FDA approval requires that a compound's mechanism, safety, and efficacy in the target population be established through Phase 1 to Phase 3 clinical trials. Lau and Dunn, writing in Bioorganic and Medicinal Chemistry in 2018, catalogued more than 60 FDA-approved peptide drugs with verified mechanisms. As of April 2026, Li and colleagues' 2025 review in Amino Acids documented the continued expansion of the therapeutic-peptide landscape, with the FDA-approved subset growing steadily across metabolic, oncologic, and endocrine indications. Selected examples with mechanism context:

• Semaglutide (Ozempic, Wegovy): GLP-1 receptor agonist. Binds GLP-1R on pancreatic beta cells (glucose-dependent insulin release), hypothalamus (appetite suppression), and GI tract (gastric emptying delay). Approved for type 2 diabetes and chronic weight management.
• Tirzepatide (Mounjaro, Zepbound): Dual GIP/GLP-1 receptor agonist. Simultaneously engages two incretin receptor types for additive metabolic effects. Mounjaro is approved for glycemic control in type 2 diabetes; Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity (approved December 2024).
• Tesamorelin (Egrifta): Stabilized GHRH analogue. Stimulates the pituitary to release endogenous growth hormone. Approved for HIV-associated lipodystrophy.
• Teriparatide (Forteo): PTH(1-34) fragment. Binds PTH receptors on osteoblasts to stimulate bone formation. Approved for osteoporosis.
• Leuprolide (Lupron): GnRH agonist. Binds GnRH receptors in the pituitary to initially stimulate, then suppress, gonadotropin release (tachyphylaxis). Used in prostate cancer, endometriosis, and uterine fibroids.

Wang and colleagues, in their 2022 review in Signal Transduction and Targeted Therapy, reviewed receptor-specific peptide drug design across all approved therapeutic categories.

What "Safe" Means for Peptides — and What It Depends On

The safety profile of any peptide is inseparable from its mechanism. A compound that activates a receptor with broad tissue distribution will have broader effects — and broader risks — than one with highly localized receptor expression. That mechanistic reality underlies the different safety profiles across the peptide class.

FDA-approved peptides: known profiles from clinical trials

The safety of approved peptide medications is characterized by large-scale clinical trials. For GLP-1 class agents, the gastrointestinal adverse effect profile (nausea, vomiting, constipation, diarrhea) is well-documented and attributable to the mechanism: GLP-1 receptors are expressed in the GI tract, and agonism slows gastric motility as a direct pharmacological effect. Chandarana and colleagues, in their 2024 review in Current Drug Research Reviews, noted peptide therapeutic selectivity and toxicity profile relative to small-molecule drugs — high specificity and relatively low systemic toxicity — reflecting the receptor-targeted nature of peptide pharmacology. Documented risks (e.g., cholelithiasis with GLP-1 agents) and theoretical risks (e.g., thyroid C-cell effects extrapolated from rodent data) are monitored as part of post-marketing surveillance programs. These risks are labeled and understood because the trials were completed.

Unregulated research peptides: evidence gaps and sourcing risks

Research-grade peptides lack the clinical data that characterizes their risk profile in humans. Most mechanistic evidence is from rodent or in vitro models. Gwyer and colleagues, in a 2019 review in Cell and Tissue Research, reviewed BPC-157 preclinical tissue-healing mechanisms in tendon, ligament, and muscle models — but explicitly noted that translation to human evidence remains unestablished. As of April 22, 2026, BPC-157 has been placed in FDA Category 2 under the 503A bulk drug substance framework, meaning it is no longer eligible for compounding under Section 503A pending the FDA's safety determination. Warthen and colleagues, in a 2024 review in Biomacromolecules, reviewed peptides in oncology and organ targeting while emphasizing that mechanisms established in cell culture and animal models require human validation before clinical conclusions can be drawn. Beyond efficacy uncertainty, gray-market peptide products carry manufacturing risks including contamination, incorrect concentration, and misidentification that are not mitigated by the end user.

What affects safety at the individual level

Regulatory status and manufacturing quality are the largest determinants of safety for any peptide. Beyond those factors, delivery route matters: injectable peptides bypass the GI degradation that neutralizes most oral peptides, meaning systemic exposure is higher and more predictable than with oral supplements, but so is the risk associated with injection site contamination or dosing errors. Individual biology also matters: organ function (particularly kidney and liver) affects how a compound is processed and cleared. Whether baseline biomarkers have been assessed before any peptide intervention determines whether biological changes can be detected and interpreted afterward.

Which Biomarkers Are Relevant to Peptide Science?

The mechanisms described in this article have direct counterparts in measurable bloodwork. Understanding baseline values in these markers provides the objective context needed to evaluate any response to a peptide — whether from a dietary supplement, a prescribed medication, or a research compound.

• Fasting insulin and glucose: The primary metabolic markers for GLP-1 class peptide activity. Fasting insulin and fasting glucose characterize insulin sensitivity and pancreatic beta-cell function at baseline. Changes in these values are among the most directly measured outcomes in metabolic peptide trials.
• HbA1c: A 3-month average of blood glucose, and the primary efficacy endpoint in most metabolic peptide clinical trials. A baseline HbA1c makes any subsequent glycemic change interpretable.
• IGF-1: The primary downstream marker for growth hormone axis activity. Growth hormone-releasing peptides act by increasing pituitary GH secretion, which drives IGF-1 production in the liver. A baseline IGF-1 establishes where the GH axis currently stands before any intervention.
• hs-CRP: Systemic inflammatory marker. Relevant for peptides studied in anti-inflammatory contexts. High-sensitivity CRP provides a reference point for tracking inflammatory burden over time.
• Lipid panel (total cholesterol, LDL, HDL, triglycerides): GLP-1 class agents have demonstrated effects on lipid parameters in clinical trials. A baseline triglycerides and full lipid panel reading is standard before metabolic peptide interventions.
• Kidney function (eGFR, creatinine): Renal clearance affects the pharmacokinetics of injectable peptides. Impaired kidney function can alter how compounds are eliminated. An eGFR baseline is required before many approved injectable compound protocols.
• Liver enzymes (ALT, AST): Hepatic function baseline. Standard pre-treatment assessment for any compound with hepatic metabolism. Alanine aminotransferase is a sensitive and early marker of hepatocellular stress.

Running a metabolic health biomarker test before exploring any peptide protocol establishes the objective reference points that make any subsequent biological change interpretable. Without a baseline, a change in any of these markers is a data point without context.

When These Questions Deserve Professional Attention

If the experience driving peptide research is a symptom — unexplained weight change, persistent fatigue, disordered appetite, poor metabolic function, or hormonal irregularities — those experiences deserve a clinical evaluation before any compound is considered. Primary care metabolic workups and endocrinology consultations are the appropriate pathways. Bloodwork is the starting point, not the final answer, but it provides the objective foundation for clinical decision-making.

Understanding your biology before acting on it is foundational to Superpower's approach to preventive health. In a category where the same word — "peptide" — covers both rigorously evaluated prescription medications and uncharacterized research compounds, the biological picture provided by baseline testing is the most reliable starting point available.

IMPORTANT SAFETY INFORMATION

This article discusses peptides as a broad category, including both FDA-approved medications and compounds that are not FDA-approved for any human use. Not all peptides discussed carry the same evidence base or safety profile. Superpower Health does not prescribe, sell, or facilitate access to peptide compounds that are not FDA-approved for human use.

FDA-approved peptide medications are prescription drugs that must be obtained through a licensed healthcare provider. Non-approved research peptides, often sold labeled "for research use only," are not regulated for human safety, efficacy, or manufacturing quality. Products purchased through unregulated channels may contain incorrect doses, contaminants, or misidentified compounds.

This content is not a substitute for medical advice, diagnosis, or treatment. If you are considering any peptide-based compound, consult a licensed healthcare provider before proceeding. Individual health conditions, medications, and organ function affect both suitability and response.

For information about FDA-approved peptide medications, visit dailymed.nlm.nih.gov. For FDA guidance on compounded peptides and bulk drug substance classifications, visit the FDA's compounding resource center.